Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Scheel AH"" wg kryterium: Autor


Tytuł :
High-Throughput Profiling of Colorectal Cancer Liver Metastases Reveals Intra- and Inter-Patient Heterogeneity in the EGFR and WNT Pathways Associated with Clinical Outcome.
Autorzy :
Menck K; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, 48149 Münster, Germany.; West German Cancer Center, University Hospital Münster, 48149 Münster, Germany.; Department of Hematology/Medical Oncology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Wlochowitz D; Department of Medical Bioinformatics, University Medical Center Göttingen, 37075 Göttingen, Germany.
Wachter A; Department of Medical Bioinformatics, University Medical Center Göttingen, 37075 Göttingen, Germany.
Conradi LC; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, 37075 Göttingen, Germany.
Wolff A; Department of Medical Bioinformatics, University Medical Center Göttingen, 37075 Göttingen, Germany.
Scheel AH; Department of Pathology, Universal Hospital of Köln, 50937 Köln, Germany.
Korf U; Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Wiemann S; Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Schildhaus HU; Institute of Pathology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Bohnenberger H; Institute of Pathology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Wingender E; Department of Medical Bioinformatics, University Medical Center Göttingen, 37075 Göttingen, Germany.
Pukrop T; Department of Hematology/Medical Oncology, University Medical Center Göttingen, 37075 Göttingen, Germany.; Clinic for Internal Medicine III, Hematology and Medical Oncology, University Regensburg, 93053 Regensburg, Germany.
Homayounfar K; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, 37075 Göttingen, Germany.
Beißbarth T; Department of Medical Bioinformatics, University Medical Center Göttingen, 37075 Göttingen, Germany.
Bleckmann A; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, 48149 Münster, Germany.; West German Cancer Center, University Hospital Münster, 48149 Münster, Germany.; Department of Hematology/Medical Oncology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Pokaż więcej
Źródło :
Cancers [Cancers (Basel)] 2022 Apr 21; Vol. 14 (9). Date of Electronic Publication: 2022 Apr 21.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Autorzy :
Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Wiesweg M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Michels S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Nogová L; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Kron A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Herold T; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Scheel AH; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Metzenmacher M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Eberhardt WE; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Reis H; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Fassunke J; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Darwiche K; Department of Pulmonary Medicine, Section of Interventional Pneumology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Aigner C; Department of Thoracic Surgery and Endoscopy, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany.
Schaufler D; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Riedel R; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Fischer R; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Koleczko S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Schildhaus HU; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Merkelbach-Bruse S; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Schmid KW; Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
Büttner R; Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Germany.
Wolf J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Germany.
Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Germany. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Apr 16; Vol. 168, pp. 10-20. Date of Electronic Publication: 2022 Apr 16.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
Autorzy :
Saleh MM; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheel AH; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Ulmer B; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Buettner R; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Jan; Vol. 17 (1), pp. 76-88. Date of Electronic Publication: 2021 Sep 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Kelch-Like ECH-Associated Protein 1*/genetics
Lung Neoplasms*/genetics
Tumor Suppressor Protein p53*/genetics
Carcinoma, Non-Small-Cell Lung/*genetics
Humans ; Mutation ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Optimized PD-L1 scoring of gastric cancer.
Autorzy :
Schoemig-Markiefka B; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Eschbach J; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Scheel AH; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Pamuk A; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Rueschoff J; Institute of Pathology Nordhessen, Kassel, Germany.; Targos Molecular Pathology GmbH, Kassel, Germany.
Zander T; Department i of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Gastrointestinal Cancer Group Cologne GCGC, University of Cologne, Cologne, Germany.
Buettner R; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Targos Molecular Pathology GmbH, Kassel, Germany.
Schroeder W; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Bruns CJ; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Loeser H; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Alakus H; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Quaas A; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. .
Pokaż więcej
Źródło :
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2021 Sep; Vol. 24 (5), pp. 1115-1122. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
B7-H1 Antigen*
Stomach Neoplasms*/surgery
Biomarkers, Tumor/analysis ; Biopsy ; Humans ; Immunohistochemistry
Czasopismo naukowe
Tytuł :
Improved Tissue Processing in Esophageal Adenocarcinoma After Ivor Lewis Esophagectomy Allows Histological Analysis of All Surgically Removed Lymph Nodes with Significant Effects on Nodal UICC Stages.
Autorzy :
Quaas A; Institute of Pathology, Gastrointestinal Cancer Group Cologne (GCGC), University Hospital Cologne, Cologne, Germany. .
Schloesser H; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Fuchs H; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Zander T; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Arolt C; Institute of Pathology, Gastrointestinal Cancer Group Cologne (GCGC), University Hospital Cologne, Cologne, Germany.
Scheel AH; Institute of Pathology, Gastrointestinal Cancer Group Cologne (GCGC), University Hospital Cologne, Cologne, Germany.
Rueschoff J; Institute of Pathology, Nordhessen and Targos Molecular Pathology GmbH, Kassel, Germany.
Bruns C; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Buettner R; Institute of Pathology, Gastrointestinal Cancer Group Cologne (GCGC), University Hospital Cologne, Cologne, Germany.
Schroeder W; Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2021 Jul; Vol. 28 (7), pp. 3975-3982. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Adenocarcinoma*/surgery
Esophageal Neoplasms*/pathology
Esophageal Neoplasms*/surgery
Esophagectomy ; Humans ; Lymph Node Excision ; Lymph Nodes/pathology ; Lymph Nodes/surgery ; Neoplasm Staging ; Prognosis
Czasopismo naukowe
Tytuł :
Lymphangiosis carcinomatosa independently affects long-term survival of Non-Small Cell Lung Cancer patients.
Autorzy :
Heldwein MB; Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany. Electronic address: .
Doerr F; Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany.
Schlachtenberger G; Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany.
Menghesha H; Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany.
Kuhn EW; Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany.
Scheel AH; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Michel M; Institute of Zoology, Faculty of Mathematics and Natural Sciences, University of Cologne, Germany.
Wahlers T; Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany.
Hekmat K; Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Surgical oncology [Surg Oncol] 2021 Jun; Vol. 37, pp. 101611. Date of Electronic Publication: 2021 May 31.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*mortality
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*mortality
Lung Neoplasms/*pathology
Aged ; Carcinoma, Non-Small-Cell Lung/surgery ; Female ; Humans ; Lung Neoplasms/surgery ; Lymph Node Excision ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Pneumonectomy ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
[Brain metastases-Interdisciplinary approach towards a personalized treatment].
Autorzy :
Grau S; Klinik für Allgemeine Neurochirurgie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Kerpener Str. 62, 50937, Köln, Deutschland. .; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland. .
Herling M; Klinik I für Innere Medizin, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Mauch C; Klinik für Dermatologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Galldiks N; Klinik für Neurologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Institut für Neurowissenschaften und Medizin (INM-3), Forschungszentrum Jülich, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Golla H; Zentrumfür Palliativmedizin, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Schlamann M; Institut für Radiologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Scheel AH; Institut für Pathologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Celik E; Klinik für Radioonkologie, Cyberknife und Strahlentherapie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Ruge M; Klinik für Stereotaxie und funktionelle Neurochirurgie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Goldbrunner R; Klinik für Allgemeine Neurochirurgie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Kerpener Str. 62, 50937, Köln, Deutschland.; Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
Pokaż więcej
Transliterated Title :
Hirnmetastasen – interdisziplinär zu einer personalisierten Behandlung.
Źródło :
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen [Chirurg] 2021 Mar; Vol. 92 (3), pp. 200-209. Date of Electronic Publication: 2021 Jan 27.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Brain Neoplasms*/surgery
Radiosurgery*
Combined Modality Therapy ; Humans ; Precision Medicine ; Prognosis
Czasopismo naukowe
Tytuł :
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Autorzy :
Torlakovic E; Saskatchewan Health Authority (SHA), Saskatoon, SK, Canada. .; College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. .
Lim HJ; College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Adam J; Gustave-Roussy Cancer Campus, Villejuif, France.
Barnes P; Dalhousie University, Halifax, NS, Canada.
Bigras G; Cross Cancer Institute, Edmonton, AB, Canada.
Chan AWH; The Chinese University of Hong Kong, New Territories, Hong Kong.
Cheung CC; University Health Network, Toronto, ON, Canada.; University of Toronto, Toronto, ON, Canada.
Chung JH; Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea.
Couture C; Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL), Quebec City, QC, Canada.
Fiset PO; McGill University Health Science Centre, Montreal, QC, Canada.
Fujimoto D; Kobe City Medical Center General Hospital, Kobe, Japan.
Han G; School of Public Health, Texas A&M University, College Station, TX, USA.
Hirsch FR; Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System, New York, NY, USA.
Ilie M; Hôpital Pasteur, FHU OncoAge, Biobanque BB-0033-00025, Université Côte d'Azur, CHU de Nice, Nice, France.
Ionescu D; British Columbia Cancer Agency, Vancouver, BC, Canada.
Li C; Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China.
Munari E; IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.
Okuda K; Nagoya City University Graduate School of Medical Science, Nagoya, Japan.
Ratcliffe MJ; Precision Medicine and Genomics, AstraZeneca, Cambridge, UK.
Rimm DL; Yale University School of Medicine, New Haven, CT, USA.
Ross C; Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
Røge R; Aalborg University Hospital, Aalborg, Denmark.
Scheel AH; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Soo RA; National University Hospital, Singapore, Singapore.
Swanson PE; University of Washington, Seattle, WA, USA.; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Tretiakova M; University of Washington, Seattle, WA, USA.
To KF; University Health Network, Toronto, ON, Canada.
Vainer GW; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Wang H; McGill University Health Center and McGill University, Montreal, QC, Canada.
Xu Z; Cross Cancer Institute, Edmonton, AB, Canada.
Zielinski D; TARGOS Molecular Pathology GmbH, Kassel, Germany.
Tsao MS; University Health Network, Toronto, ON, Canada.; University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło :
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2020 Jan; Vol. 33 (1), pp. 4-17. Date of Electronic Publication: 2019 Aug 05.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
B7-H1 Antigen/*analysis
Immunohistochemistry/*methods
Humans ; Immunohistochemistry/standards
Czasopismo naukowe
Tytuł :
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Autorzy :
Di Tacchio M; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Macas J; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.
Weissenberger J; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.
Sommer K; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.
Bähr O; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.; Senckenberg Institute of Neurooncology, University Hospital, Goethe University, Frankfurt, Germany.
Steinbach JP; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.; Senckenberg Institute of Neurooncology, University Hospital, Goethe University, Frankfurt, Germany.
Senft C; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurosurgery, University Hospital, Goethe University, Frankfurt, Germany.
Seifert V; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurosurgery, University Hospital, Goethe University, Frankfurt, Germany.
Glas M; Department of Neurology, Division of Clinical Neurooncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.; DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Herrlinger U; Department of Neurology, Division of Clinical Neurooncology, University of Bonn Medical Centre, Bonn, Germany.
Krex D; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurosurgery, Dresden University of Technology, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
Meinhardt M; Institute of Pathology, Dresden University of Technology, Dresden, Germany.
Weyerbrock A; Department of Neurosurgery, Medical Center-University of Freiburg, Freiburg, Germany.
Timmer M; Center for Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Goldbrunner R; Center for Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Deckert M; Institute of Neuropathology, University Hospital of Cologne, Cologne, Germany.
Scheel AH; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Büttner R; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
Grauer OM; Department of Neurology with Institute of Translational Neurology, University Hospital of Muenster, Muenster, Germany.
Schittenhelm J; Department of Neuropathology, Institute of Pathology and Neuropathology, Eberhard-Karls University Tuebingen, Tuebingen, Germany.
Tabatabai G; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Departments of Neurology & Neurosurgery, Interdisciplinary Division of Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for CNS Tumors, Comprehensive Cancer Center, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tübingen, Tübingen, Germany.
Harter PN; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.
Günther S; Max Planck Institute for Heart and Lung Research, Bioinformatics and Deep Sequencing Platform, Bad Nauheim, Germany.
Devraj K; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.
Plate KH; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.
Reiss Y; Institute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt, Germany. .; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Frankfurt Cancer Institute, Frankfurt, Germany.
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2019 Dec; Vol. 7 (12), pp. 1910-1927. Date of Electronic Publication: 2019 Oct 09.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Angiopoietin-2/*antagonists & inhibitors
Antineoplastic Agents, Immunological/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Brain Neoplasms/*drug therapy
Glioblastoma/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
Animals ; Bevacizumab/therapeutic use ; Brain/blood supply ; Brain Neoplasms/blood supply ; Brain Neoplasms/immunology ; Brain Neoplasms/mortality ; Cell Line, Tumor ; Female ; Glioblastoma/blood supply ; Glioblastoma/immunology ; Glioblastoma/mortality ; Humans ; Immune Tolerance/drug effects ; Mice, Inbred C57BL
Czasopismo naukowe
Tytuł :
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Autorzy :
Michels S; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Massutí B; Department of Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain.
Schildhaus HU; Institute of Pathology, University Hospital Goettingen, Göttingen, Germany and Targos Molecular Pathology, Kassel, Germany.
Franklin J; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Sebastian M; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Grohé C; Department of Pneumology, Protestant Lung Hospital Berlin, Berlin, Germany.
Rodriguez-Abreu D; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Abdulla DSY; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Bischoff H; Thoraxonkologie, Thoraxklinik, Heidelberg, Germany.
Brandts C; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Carcereny E; Servei d'Oncologia Mèdica, Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, Carretera de Canyet, Badalona, Spain.
Corral J; Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; prior affiliation during the trial: Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Dingemans AC; Department for Oncology, Maastricht University Medical Center, Maastricht, Netherlands.
Pereira E; Spanish Lung Cancer Group, Barcelona, Spain.
Fassunke J; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Fischer RN; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Gardizi M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Heukamp L; Institute of Hematopatholgy Hamburg, Hamburg, Germany, and Lung Cancer Network NOWEL, Oldenburg, Germany.
Insa A; Hospital Clínico Universitario de Valencia, València, Spain.
Kron A; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Menon R; NEO New Oncology GmbH, Cologne, Germany.
Persigehl T; Department of Radiology, University Hospital Cologne, Cologne, Germany.
Reck M; Department for Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research, LungenClinic Grosshansdorf, Großhansdorf, Germany.
Riedel R; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rothschild SI; University Hospital Basel, Department Internal Medicine, Medical Oncology, Basel, Switzerland.
Scheel AH; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Schmalz P; Clinical Trials Centre Cologne (CTCC) Medical Faculty, University of Cologne, Cologne, Germany.
Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Limburg M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Provencio M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Spain.
Karachaliou N; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Hellmich M; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Nogova L; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Büttner R; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Jul; Vol. 14 (7), pp. 1266-1276. Date of Electronic Publication: 2019 Apr 09.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Rearrangement*
Brain Neoplasms/*drug therapy
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/genetics ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Response Evaluation Criteria in Solid Tumors ; Survival Rate
Czasopismo naukowe
Tytuł :
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
Autorzy :
Thangarajah F; Department of Obstetrics and Gynaecology, Medical Faculty, University Hospital Cologne, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany. .
Morgenstern B; Department of Obstetrics and Gynaecology, Medical Faculty, University Hospital Cologne, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.
Pahmeyer C; Department of Obstetrics and Gynaecology, Medical Faculty, University Hospital Cologne, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.
Schiffmann LM; Department of General, Visceral and Cancer Surgery, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Puppe J; Department of Obstetrics and Gynaecology, Medical Faculty, University Hospital Cologne, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.
Mallmann P; Department of Obstetrics and Gynaecology, Medical Faculty, University Hospital Cologne, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.
Hamacher S; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Buettner R; Department of Pathology, University Hospital of Cologne, Institute of Pathology, Kerpener Str. 62, 50937, Cologne, Germany.
Alidousty C; Department of Pathology, University Hospital of Cologne, Institute of Pathology, Kerpener Str. 62, 50937, Cologne, Germany.
Holz B; Department of Pathology, University Hospital of Cologne, Institute of Pathology, Kerpener Str. 62, 50937, Cologne, Germany.
Scheel AH; Department of Pathology, University Hospital of Cologne, Institute of Pathology, Kerpener Str. 62, 50937, Cologne, Germany.
Schultheis AM; Department of Pathology, University Hospital of Cologne, Institute of Pathology, Kerpener Str. 62, 50937, Cologne, Germany. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2019 Jun; Vol. 145 (6), pp. 1651-1660. Date of Electronic Publication: 2019 Apr 10.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Squamous Cell/*metabolism
Programmed Cell Death 1 Receptor/*biosynthesis
Vulvar Neoplasms/*metabolism
Aged ; B7-H1 Antigen/biosynthesis ; B7-H1 Antigen/immunology ; Biomarkers, Tumor/biosynthesis ; Biomarkers, Tumor/immunology ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/pathology ; Female ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasm Staging ; Prognosis ; Programmed Cell Death 1 Receptor/immunology ; Vulvar Neoplasms/immunology ; Vulvar Neoplasms/pathology
Czasopismo naukowe
Tytuł :
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Autorzy :
Scheffler M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ihle MA; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Hein R; University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
Merkelbach-Bruse S; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Scheel AH; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Siemanowski J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Brägelmann J; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Kron A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Abedpour N; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Ueckeroth F; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Schüller M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Koleczko S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Michels S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fassunke J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Pasternack H; Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Center for Medicine and Biosciences.
Heydt C; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Serke M; Lung Clinic Hemer, Department for Pulmonology and Thoracic Oncology, Hemer, Germany.
Fischer R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Schulte W; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Gerigk U; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Nogova L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ko YD; Evangelical Clinics of Bonn, Johanniter Hospital, Bonn, Germany.
Abdulla DSY; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Riedel R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Kambartel KO; Bethanien Hospital Moers, Lung Center, Moers, Germany.
Lorenz J; Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany.
Sauerland I; Hospital Lüdenscheid, Clinic for Pneumology, Internistic Intensive Medicine, Infectiology and Sleep Medicine, Lüdenscheid, Germany.
Randerath W; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Kaminsky B; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Hagmeyer L; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Grohé C; Evangelic Lung Clinic Berlin, Department of Respiratory Diseases, Berlin, Germany.
Eisert A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Frank R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Gogl L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Schaepers C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Holzem A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Hellmich M; University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.
Thomas RK; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Peifer M; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Sos ML; University of Cologne, Department for Translational Genomics, Cologne, Germany.
Büttner R; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wolf J; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Apr; Vol. 14 (4), pp. 606-616. Date of Electronic Publication: 2018 Dec 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation
Czasopismo naukowe
Tytuł :
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.
Autorzy :
Michels S; University Hospital of Cologne, Cologne, Germany.
Heydt C; University Hospital of Cologne, Cologne, Germany.
van Veggel B; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Deschler-Baier B; University Hospital of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Pardo N; Vall d'Hebron University Hospital, Barcelona, Spain.
Monkhorst K; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rüsseler V; University Hospital of Cologne, Cologne, Germany.
Stratmann J; University Hospital of Frankfurt, Frankfurt, Germany.
Griesinger F; Pius Hospital Oldenburg and Lung Cancer Network NOWEL, Oldenburg, Germany.
Steinhauser S; University of Cologne, Cologne, Germany.
Kostenko A; University Hospital of Cologne, Cologne, Germany.
Diebold J; Cantonal Hospital Lucerne, Lucerne, Switzerland.
Fassunke J; University Hospital of Cologne, Cologne, Germany.
Fischer R; University Hospital of Cologne, Cologne, Germany.
Engel-Riedel W; Lung Clinic Merheim and Hospitals of Cologne, Cologne, Germany.
Gautschi O; Cantonal Hospital Lucerne, Lucerne, Switzerland.
Geissinger E; University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Haneder S; University Hospital of Cologne, Cologne, Germany.
Ihle MA; University Hospital of Cologne, Cologne, Germany.
Kopp HG; Robert Bosch Centrum für Tumorerkrankungen, Stuttgart, Germany.
de Langen AJ; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Martinez-Marti A; Vall d'Hebron University Hospital, Barcelona, Spain.
Nogova L; University Hospital of Cologne, Cologne, Germany.
Persigehl T; University Hospital of Cologne, Cologne, Germany.
Plenker D; University Hospital of Cologne, Cologne, Germany.
Puesken M; University Hospital of Cologne, Cologne, Germany.
Rodermann E; Private practice in Hematology and Oncology, Troisdorf, Germany.
Rosenwald A; University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Scheel AH; University Hospital of Cologne, Cologne, Germany.
Scheffler M; University Hospital of Cologne, Cologne, Germany.
Spengler W; University Hospital of Tübingen. Tübingen, Germany.
Seggewiss-Bernhardt R; Sozialstiftung Bamberg, Bamberg, Germany.
Brägelmann J; University Hospital of Cologne, Cologne, Germany.; University of Cologne, Cologne, Germany.
Sebastian M; University Hospital of Frankfurt, Frankfurt, Germany.
Vrugt B; University Hospital Zurich, Zurich, Switzerland.
Hellmich M; University of Cologne, Cologne, Germany.
Sos ML; University Hospital of Cologne, Cologne, Germany.; University of Cologne, Cologne, Germany.
Heukamp LC; Hematopathology Hamburg and Lung Cancer Network NOWEL, Hamburg, Germany.
Felip E; Vall d'Hebron University Hospital, Barcelona, Spain.
Merkelbach-Bruse S; University Hospital of Cologne, Cologne, Germany.
Smit EF; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Büttner R; University Hospital of Cologne, Cologne, Germany.
Wolf J; University Hospital of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
JCO precision oncology [JCO Precis Oncol] 2019 Mar 27; Vol. 3. Date of Electronic Publication: 2019 Mar 27 (Print Publication: 2019).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Overcoming EGFR -mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.
Autorzy :
Fassunke J; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Müller F; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Keul M; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Michels S; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Dammert MA; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Schmitt A; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.; Department I of Internal Medicine, University Hospital of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Joseph Stelzmann Str. 26, 50931, Cologne, Germany.
Plenker D; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Lategahn J; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Heydt C; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Brägelmann J; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Tumbrink HL; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Alber Y; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Klein S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Weyertal 115b, 50931, Cologne, Germany.
Heimsoeth A; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Dahmen I; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Fischer RN; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Ihle MA; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Priesner V; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Scheel AH; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Wagener S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Kron A; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Frank K; Section Pneumology, Clinic III of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Garbert K; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Persigehl T; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Püsken M; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Haneder S; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Schaaf B; Hospital Dortmund gGmbH, Muensterstrasse 240, 44145, Dortmund, Germany.
Rodermann E; Onkologie Rhein-Sieg, Schloßstraße 18, 53840, Troisdorf, Germany.
Engel-Riedel W; Department of Pneumology, Lung Hospital Cologne Merheim, City of Cologne Municipal Hospitals, Cologne, Germany.
Felip E; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Smit EF; Thoracic Oncology Service, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Merkelbach-Bruse S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Reinhardt HC; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.; Department I of Internal Medicine, University Hospital of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Joseph Stelzmann Str. 26, 50931, Cologne, Germany.
Kast SM; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Wolf J; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany. .
Rauh D; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany. .
Büttner R; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. .; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany. .; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany. .
Sos ML; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. .; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany. .; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2018 Nov 07; Vol. 9 (1), pp. 4655. Date of Electronic Publication: 2018 Nov 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Neoplasm/*drug effects
ErbB Receptors/*antagonists & inhibitors
Piperazines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Acrylamides ; Aniline Compounds ; Animals ; Cell Line, Tumor ; Disease Progression ; ErbB Receptors/chemistry ; ErbB Receptors/metabolism ; Female ; Humans ; Kinetics ; Mice ; Mice, Nude ; Mutation/genetics ; NIH 3T3 Cells ; Piperazines/chemistry ; Protein Binding/drug effects ; Protein Conformation ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Tytuł :
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
Autorzy :
Alidousty C; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Baar T; University of Cologne, Faculty of Medicine, Institute of Medical Statistics and Computational Biology, Cologne, Germany.
Martelotto LG; Monash University, Monash Health, Clayton, Victoria, Australia.
Heydt C; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Wagener S; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Fassunke J; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Duerbaum N; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Scheel AH; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Frank S; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Holz B; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Binot E; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Kron A; Network Genomic Medicine, Cologne, Germany.
Merkelbach-Bruse S; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Ihle MA; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Wolf J; Network Genomic Medicine, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.; Center for Integrated Oncology Cologne Bonn, Germany.
Buettner R; University Hospital Cologne, Institute of Pathology, Cologne, Germany.; Network Genomic Medicine, Cologne, Germany.; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Schultheis AM; University Hospital Cologne, Institute of Pathology, Cologne, Germany.
Pokaż więcej
Źródło :
The Journal of pathology [J Pathol] 2018 Sep; Vol. 246 (1), pp. 67-76. Date of Electronic Publication: 2018 Jul 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Amplification*
Genomic Instability*
Mutation*
Translocation, Genetic*
Anaplastic Lymphoma Kinase/*genetics
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Proto-Oncogene Proteins c-myc/*genetics
Tumor Suppressor Protein p53/*genetics
Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase/metabolism ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Proliferation ; Female ; Genetic Predisposition to Disease ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/pathology ; Male ; Microtubule-Associated Proteins/genetics ; Microtubule-Associated Proteins/metabolism ; Middle Aged ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Phenotype ; Proto-Oncogene Proteins c-myc/metabolism ; Serine Endopeptidases/genetics ; Serine Endopeptidases/metabolism ; Signal Transduction ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł :
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
Autorzy :
Plenker D; Molecular Pathology, Institute of Pathology, University of Cologne, Cologne, Germany.; Department of Translational Genomics, Medical Faculty, University of Cologne, Cologne, Germany.
Bertrand M; NEO New Oncology GmbH, Köln, Germany.
de Langen AJ; Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, the Netherlands.
Riedel R; Department of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, Germany.
Lorenz C; Molecular Pathology, Institute of Pathology, University of Cologne, Cologne, Germany.; Department of Translational Genomics, Medical Faculty, University of Cologne, Cologne, Germany.
Scheel AH; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Müller J; NEO New Oncology GmbH, Köln, Germany.
Brägelmann J; Molecular Pathology, Institute of Pathology, University of Cologne, Cologne, Germany.; Department of Translational Genomics, Medical Faculty, University of Cologne, Cologne, Germany.
Daßler-Plenker J; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Kobe C; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
Persigehl T; Department of Radiology, University Hospital of Cologne, Cologne, Germany.
Kluge A; Institute for Diagnostic and Interventional Radiology, Pius-Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany.
Wurdinger T; Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.; Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, Charlestown, Massachusetts.
Schellen P; Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.; Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Hartmann G; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Zacherle T; NEO New Oncology GmbH, Köln, Germany.
Menon R; NEO New Oncology GmbH, Köln, Germany.
Thunnissen E; Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
Büttner R; Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Griesinger F; Lung Cancer Network NOWEL, Oldenburg, Germany.; Department of Hematology and Oncology, Pius-Hospital, University Department Internal Medicine-Oncology, Medical Campus University of Oldenburg, Oldenburg, Germany.
Wolf J; Department of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, Germany.
Heukamp L; NEO New Oncology GmbH, Köln, Germany.; Lung Cancer Network NOWEL, Oldenburg, Germany.; Institute for Hematopathology, Hamburg, Germany.
Sos ML; Molecular Pathology, Institute of Pathology, University of Cologne, Cologne, Germany. .; Department of Translational Genomics, Medical Faculty, University of Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Heuckmann JM; NEO New Oncology GmbH, Köln, Germany. .
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Mar 15; Vol. 24 (6), pp. 1337-1343. Date of Electronic Publication: 2017 Dec 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma of Lung/*genetics
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins c-met/*antagonists & inhibitors
Proto-Oncogene Proteins c-met/*genetics
Adenocarcinoma of Lung/diagnosis ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/metabolism ; Adult ; Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Crizotinib/pharmacology ; Crizotinib/therapeutic use ; Female ; Gene Duplication ; Gene Rearrangement ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Staging ; Oncogene Proteins, Fusion/chemistry ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Protein Binding ; Protein Interaction Domains and Motifs ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-met/chemistry ; Tomography, X-Ray Computed
Czasopismo naukowe
Tytuł :
Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Autorzy :
Scheel AH; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. andreas.scheel@uk-koeln.de.
Penault-Llorca F; Département de Pathologie, Centre Jean-Perrin, 58, rue Montalembert, 392, 63011, Clermont-Ferrand cedex 1, BP, France.
Hanna W; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Baretton G; Institute of Pathology, University Hospital Dresden, Fetscherstr, 74, 01307, Dresden, Germany.
Middel P; Institute of Pathology Nordhessen, Germaniastraße 7, 34119, Kassel, Germany.; Institute of Pathology, University Hospital Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
Burchhardt J; Institute of Pathology Nordhessen, Germaniastraße 7, 34119, Kassel, Germany.
Hofmann M; Institute of Pathology Nordhessen, Germaniastraße 7, 34119, Kassel, Germany.
Jasani B; Targos Molecular Pathology GmbH, Germaniastraße 7, 34119, Kassel, Germany.
Rüschoff J; Institute of Pathology Nordhessen, Germaniastraße 7, 34119, Kassel, Germany.; Targos Molecular Pathology GmbH, Germaniastraße 7, 34119, Kassel, Germany.
Pokaż więcej
Źródło :
Diagnostic pathology [Diagn Pathol] 2018 Mar 12; Vol. 13 (1), pp. 19. Date of Electronic Publication: 2018 Mar 12.
Typ publikacji :
Journal Article
MeSH Terms :
Immunohistochemistry*/methods
Breast Neoplasms/*pathology
Receptor, ErbB-2/*metabolism
Stomach Neoplasms/*pathology
Biomarkers, Tumor/metabolism ; Breast/pathology ; Breast Neoplasms/diagnosis ; Female ; Humans ; In Situ Hybridization, Fluorescence/methods ; Receptor, ErbB-2/genetics ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/genetics
Czasopismo naukowe
Tytuł :
Current PD-L1 immunohistochemistry for non-small cell lung cancer.
Autorzy :
Scheel AH; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Schäfer SC; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Journal of thoracic disease [J Thorac Dis] 2018 Mar; Vol. 10 (3), pp. 1217-1219.
Typ publikacji :
Editorial; Comment
Opinia redakcyjna
Tytuł :
Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Autorzy :
Scheel AH; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Baenfer G; Targos Molecular Pathology GmbH, Kassel, Germany.
Baretton G; Institute of Pathology, University Hospital Dresden, Dresden, Germany.
Dietel M; Institute of Pathology, Charité-University Hospital Berlin, Berlin, Germany.
Diezko R; Targos Molecular Pathology GmbH, Kassel, Germany.
Henkel T; Targos Molecular Pathology GmbH, Kassel, Germany.
Heukamp LC; Institute for Haematopathology Hamburg, Hamburg, Germany.
Jasani B; Targos Molecular Pathology GmbH, Kassel, Germany.
Jöhrens K; Institute of Pathology, Charité-University Hospital Berlin, Berlin, Germany.
Kirchner T; Institute of Pathology, LMU University Hospital Munich, Munich, Germany.
Lasitschka F; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Petersen I; Institute of Pathology, University Hospital Jena, Jena, Germany.
Reu S; Institute of Pathology, LMU University Hospital Munich, Munich, Germany.
Schildhaus HU; Institute of Pathology, University Hospital Göttingen, Göttingen, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Schwamborn K; Institute of Pathology, TUM University Hospital Munich, Munich, Germany.
Sommer U; Institute of Pathology, University Hospital Dresden, Dresden, Germany.
Stoss O; Targos Molecular Pathology GmbH, Kassel, Germany.
Tiemann M; Institute for Haematopathology Hamburg, Hamburg, Germany.
Warth A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Weichert W; Institute of Pathology, TUM University Hospital Munich, Munich, Germany.
Wolf J; Medical Clinic I, University Hospital Cologne, Cologne, Germany.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.; Targos Molecular Pathology GmbH, Kassel, Germany.
Rüschoff J; Targos Molecular Pathology GmbH, Kassel, Germany.; Institute of Pathology Nordhessen, Kassel, Germany.
Pokaż więcej
Źródło :
Histopathology [Histopathology] 2018 Feb; Vol. 72 (3), pp. 449-459. Date of Electronic Publication: 2017 Nov 21.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
B7-H1 Antigen/*analysis
Biomarkers, Tumor/*analysis
Carcinoma, Non-Small-Cell Lung/*diagnosis
Immunohistochemistry/*standards
Lung Neoplasms/*diagnosis
Humans ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC - Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ).
Autorzy :
Petersen I; Institute of Pathology, Jena University Hospital, Germany. Electronic address: .
Dietel M; Institute of Pathology, Charité - University Medicine Berlin, Germany; Quality Assurance Initiative for Pathology (QuIP - Quality in Pathology) GmbH, Berlin, Germany.
Geilenkeuser WJ; Reference Institute for Bioanalytics (RfB), Bonn, Germany.
Mireskandari M; Institute of Pathology, Jena University Hospital, Germany.
Weichert W; Institute of Pathology, Technical University Munich, Germany.
Steiger K; Institute of Pathology, Technical University Munich, Germany.
Scheel AH; Institute of Pathology, University Hospital Cologne, Germany.
Büttner R; Institute of Pathology, University Hospital Cologne, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Germany.
Warth A; Institute of Pathology, University Hospital Heidelberg, Germany.
Lasitschka F; Institute of Pathology, University Hospital Heidelberg, Germany.
Schildhaus HU; Institute of Pathology, University Hospital Göttingen, Germany.
Kirchner T; Institute of Pathology, Ludwig-Maximilian University Munich, Germany.
Reu S; Institute of Pathology, Ludwig-Maximilian University Munich, Germany.
Kreipe H; Institute of Pathology, Hannover Medical School, Hannover, Germany.
Länger F; Institute of Pathology, Hannover Medical School, Hannover, Germany.
Tiemann M; Institute for Hematopathology, Hamburg, Germany.
Schulte C; Institute for Hematopathology, Hamburg, Germany.
Jöhrens K; Institute of Pathology, Charité - University Medicine Berlin, Germany.
Pokaż więcej
Źródło :
Pathology, research and practice [Pathol Res Pract] 2017 Dec; Vol. 213 (12), pp. 1530-1535. Date of Electronic Publication: 2017 Sep 28.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*pathology
Carcinoma, Non-Small-Cell Lung/*therapy
ErbB Receptors/*metabolism
Lung Neoplasms/*metabolism
Lung Neoplasms/*pathology
Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers/analysis ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/therapy ; Humans ; Immunohistochemistry/methods ; Lung Neoplasms/therapy ; Reproducibility of Results
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies